Most cancer drugs approved by European regulators over a four-year period lack evidence of high clinical benefit, analysis finds

A newly published analysis reported by Stat News finds that most cancer drugs approved by European regulators over a recent four-year period did not meet thresholds for high clinical benefit at the time of authorisation. The analysis, details of which were reported at or around the ESMO 2026 meeting in Madrid, examined medicines approved by the European Medicines Agency (EMA) and assessed them against established frameworks for rating the magnitude of clinical benefit — such as the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

The findings are consistent with a body of prior literature — including analyses published in the BMJ and JAMA Oncology — that has raised sustained questions about whether regulatory approval thresholds for oncology medicines adequately reflect clinical meaningfulness for patients. Approval may be granted on the basis of surrogate endpoints (such as progression-free survival or tumour response rate) that do not always translate into improvements in overall survival or quality of life.

The analysis has relevance for health technology assessment bodies, payers, and oncology researchers evaluating the real-world value of the cancer drug pipeline. The primary source for this item is a Stat News report; the full underlying analysis had not, at time of publication, been verified against a peer-reviewed journal article.